Search

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

In Memoriam Professor Emeritus Michel Symann

Dear Colleagues,

My dear friend Professor Emeritus Michel Symann passed away on April 23, 2023 at the age of 81.

Read more